Literature DB >> 22429025

Changes in glucose metabolism and metabolites during the epileptogenic process in the lithium-pilocarpine model of epilepsy.

Eun Mi Lee1, Ga Young Park, Ki Chun Im, Sang Tae Kim, Chul-Woong Woo, Jin Hwa Chung, Ki Soo Kim, Jae Seung Kim, Young-Min Shon, Yeong In Kim, Joong Koo Kang.   

Abstract

PURPOSE: The metabolic and biochemical changes that occur during epileptogenesis remain to be determined. (18) F-Fluorodeoxyglucose positron emission tomography (FDG-PET) and proton magnetic resonance spectroscopy ((1) H MRS) are noninvasive techniques that provide indirect information on ongoing pathologic changes. We, therefore, utilized these methods to assess changes in glucose metabolism and metabolites in the rat lithium-pilocarpine model of epilepsy as markers of epileptogenesis from baseline to chronic spontaneous recurrent seizures (SRS).
METHODS: PET and MRS were performed at baseline, and during the acute, subacute, silent, and chronic periods after lithium-pilocarpine induced status epilepticus (SE). Sequential changes in glucose metabolism on (18) F-FDG PET using SPM2 and the ratios of percent injected dose per gram (%ID)/g of regions of interest (ROIs) in the bilateral amygdala, hippocampus, basal ganglia with the thalamus, cortex, and hypothalamus normalized to the pons were determined. Voxels of interest (VOIs) on (1) H MRS were obtained at the right hippocampus and the basal ganglia. NAA/Cr levels and Cho/Cr at various time points were compared to baseline values. KEY
FINDINGS: Of 81 male Sprague-Dawley rats, 30 progressed to SRS. (18) F-FDG PET showed widespread global hypometabolism during the acute period, returning to baseline level during the subacute period. Glucose metabolism, however, declined in part of the hippocampus during the silent period, with the hypometabolic area progressively expanding to the entire limbic area during the chronic period. (1) H MRS showed that the NAA/Cr levels in the hippocampus and basal ganglia were reduced during the acute period and were not restored subsequently from the subacute to the chronic period without any significant change in the Cho/Cr ratio throughout the entire experiment. SIGNIFICANCE: Serial metabolic and biochemical changes in the lithium-pilocarpine model of epilepsy indirectly represent the process of human epileptogenesis. Following initial irreversible neural damage by SE, global glucose metabolism transiently recovered during the subacute period without neuronal recovery. Progressive glucose hypometabolism in the limbic area during the silent and chronic periods may reflect the important role of the hippocampus in the formation of ongoing epileptic network during epileptogenesis. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429025     DOI: 10.1111/j.1528-1167.2012.03432.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  26 in total

1.  Inhalation of Shin-I essential oil enhances lactate clearance in treadmill exercise.

Authors:  Hsuan-Ying Chen; Ming-Fu Wang; Jun-Ying Lin; Ying-Chieh Tsai; Fu-Chou Cheng
Journal:  Asian Pac J Trop Biomed       Date:  2014-02

2.  Quantitative SPM Analysis Involving an Adaptive Template May Be Easily Applied to [18F]FDG PET Images of the Rat Brain.

Authors:  Sylvain Poussier; Fatiha Maskali; Gaelle Vexiau; Antoine Verger; Henri Boutley; Gilles Karcher; Emmanuel Raffo; Pierre-Yves Marie
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

Review 3.  Neuroimaging the epileptogenic process.

Authors:  Sandy R Shultz; Terence J O'Brien; Maria Stefanidou; Ruben I Kuzniecky
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

4.  Serotonin Depletion Does not Modify the Short-Term Brain Hypometabolism and Hippocampal Neurodegeneration Induced by the Lithium-Pilocarpine Model of Status Epilepticus in Rats.

Authors:  Luis García-García; Ahmed Anis Shiha; Pablo Bascuñana; Javier de Cristóbal; Rubén Fernández de la Rosa; Mercedes Delgado; Miguel A Pozo
Journal:  Cell Mol Neurobiol       Date:  2015-07-25       Impact factor: 5.046

5.  Mitochondrial respiration deficits driven by reactive oxygen species in experimental temporal lobe epilepsy.

Authors:  Shane Rowley; Li-Ping Liang; Ruth Fulton; Takahiko Shimizu; Brian Day; Manisha Patel
Journal:  Neurobiol Dis       Date:  2015-01-17       Impact factor: 5.996

6.  Early hypoactivity of hippocampal rhythms during epileptogenesis after prolonged febrile seizures in freely-moving rats.

Authors:  Bo Feng; Yang-Shun Tang; Bin Chen; Zheng-Hao Xu; Yi Wang; Deng-Chang Wu; Hua-Wei Zhao; Shi-Hong Zhang; Zhong Chen
Journal:  Neurosci Bull       Date:  2015-04-26       Impact factor: 5.203

Review 7.  Modulation of Glucose Availability and Effects of Hypo- and Hyperglycemia on Status Epilepticus: What We Do Not Know Yet?

Authors:  Igor Santana de Melo; Amanda Larissa Dias Pacheco; Yngrid Mickaelli Oliveira Dos Santos; Laura Mello Figueiredo; Dannyele Cynthia Santos Pimentel Nicacio; Leia Cardoso-Sousa; Marcelo Duzzioni; Daniel Leite Góes Gitaí; Cristiane Queixa Tilelli; Robinson Sabino-Silva; Olagide Wagner de Castro
Journal:  Mol Neurobiol       Date:  2020-09-25       Impact factor: 5.590

Review 8.  Neuroimaging biomarkers for epilepsy: advances and relevance to glial cells.

Authors:  Andre Obenaus
Journal:  Neurochem Int       Date:  2013-05-09       Impact factor: 3.921

9.  Workshop on Neurobiology of Epilepsy appraisal: new systemic imaging technologies to study the brain in experimental models of epilepsy.

Authors:  Stefanie Dedeurwaerdere; Sandy R Shultz; Paolo Federico; Jerome Engel
Journal:  Epilepsia       Date:  2014-05-16       Impact factor: 5.864

10.  [(18)F]FDG PET Neuroimaging Predicts Pentylenetetrazole (PTZ) Kindling Outcome in Rats.

Authors:  Pablo Bascuñana; Julián Javela; Mercedes Delgado; Rubén Fernández de la Rosa; Ahmed Anis Shiha; Luis García-García; Miguel Ángel Pozo
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.